瘤性简单疹病毒,旨在针对EGFR携带瘤的向治疗
Selene Ingusci1, Bonnie L Hall1, Justus B Cohen1
1Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA 15219, USA.
Molecular therapy. Oncology
|April 10, 2024
概括
使用VHH和亲体配体的工程瘤性简单疹病毒 (oHSV) 显示了瘤向和癌细胞杀死的改进. 这些增强的oHSV证明了有效的全身癌症治疗的潜力.
科学领域:
- 瘤治疗性病毒疗法
- 分子工程是分子工程.
- 癌症治疗方法 癌症治疗方法
背景情况:
- 瘤性简单疹病毒 (oHSV) 是有前途的癌症原体.
- 针对原发性瘤和转移,需要进行瘤内和全身传递.
- 工程病毒葡萄糖蛋白通过瘤特异性细胞表面蛋白增强瘤特异性.
研究的目的:
- 为了比较工程化oHSV与不同的配体 (scFv,affibody,VHH) 在糖蛋白D (gD) 上的不同位置.
- 评估这些重定位的oHSV对EGFR表达瘤的疗效.
- 评估针对转移性疾病的目标oHSV系统传递的潜力.
主要方法:
- 通过将单链抗体 (scFv),亲体或VHH抗体连接体纳入糖蛋白D (gD) 的方法对oHSV进行工程.
- 将scFv,affibody和VHH重定位的oHSV的性能进行比较.
- 在体外评估EGFR特异性瘤细胞的进入,扩散和杀死.
- 评估长期的瘤特异性病毒复制和瘤生长减少在静脉和瘤内输送后体内.
主要成果:
- 与scFv相比,VHH和亲体配体的介导增强了EGFR特异性瘤细胞的进入,扩散和杀死.
- 工程化oHSVs在体内静脉输送后使长期瘤特异性病毒复制成为可能.
- 用VHH重定位的oHSV在静脉注射后降低了瘤生长,并在注射后实现了完全的瘤破坏.
结论:
- 与scFv相比,VHH和亲体配体在重新定位oHSV到EGFR表达细胞方面有所改善.
- 改进的针对性oHSV设计对于通过血液进行有效和安全的全身注射至关重要.
- 这些发现促进了瘤特异性oHSVs的开发,用于治疗转移性癌症.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy
522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K


